Equivalence concepts in biopharmaceuticals MCQs With Answer

Equivalence concepts in biopharmaceuticals MCQs With Answer is a focused question bank tailored for M.Pharm students studying Biological Evaluation of Drug Therapy. This collection covers core topics such as bioequivalence (BE) principles, statistical criteria, study designs, regulatory expectations for biosimilars, PK/PD considerations, BCS-based biowaivers, immunogenicity, and specialized approaches for highly variable or narrow therapeutic index drugs. Each question is crafted to deepen conceptual understanding and to mirror real-world regulatory and experimental scenarios. Use these MCQs to test knowledge, prepare for exams, and reinforce practical decision-making in designing and interpreting equivalence studies for both small molecules and biologics.

Q1. What is the standard definition of bioequivalence between two drug products?

• They contain identical excipients and manufacturing processes.
• There is no clinically significant difference in safety profiles regardless of absorption.
• There is no significant difference in the rate and extent of absorption between the two products.
• The brand and generic have identical labeling and prices.

Correct Answer: There is no significant difference in the rate and extent of absorption between the two products.

Q2. What statistical criterion is most commonly applied to demonstrate bioequivalence for AUC and Cmax?

• P-value < 0.05 for superiority testing of the test over reference.
• The 95% confidence interval for the mean difference falls within ±20%.
• The 90% confidence interval of the geometric mean ratio for AUC and Cmax lies within 80–125%.
• Non-overlapping 95% confidence intervals of mean concentrations.

Correct Answer: The 90% confidence interval of the geometric mean ratio for AUC and Cmax lies within 80–125%.

Q3. Which clinical trial design is conventionally preferred for single-dose bioequivalence studies of oral immediate-release products?

• Parallel-group randomized design in patients.
• Two-period, two-sequence crossover design in healthy volunteers.
• Open-label uncontrolled single-arm study.
• Four-arm factorial design with dose escalation.

Correct Answer: Two-period, two-sequence crossover design in healthy volunteers.

Q4. In pharmacokinetic assessment, what does Tmax represent?

• The total exposure over time measured by AUC.
• The time to reach the maximum plasma concentration (Cmax).
• The terminal elimination half-life.
• The minimum plasma concentration during dosing interval.

Correct Answer: The time to reach the maximum plasma concentration (Cmax).

Q5. For highly variable drugs (within-subject CV >30%), which approach is commonly used to improve feasibility of demonstrating bioequivalence?

• Widen the fixed 80–125% limits to 60–140% for all drugs.
• Use reference-scaled average bioequivalence (RSABE) with replicate crossover designs.
• Switch to a parallel design with very large sample size only.
• Measure only Cmax and ignore AUC.

Correct Answer: Use reference-scaled average bioequivalence (RSABE) with replicate crossover designs.

Q6. How are bioequivalence acceptance limits typically modified for narrow therapeutic index (NTI) drugs?

• They are expanded to 70–143% to reduce study failures.
• They are relaxed to 75–133% for Cmax only.
• They require tighter equivalence margins narrower than the standard 80–125%.
• No modification; standard 80–125% always applies.

Correct Answer: They require tighter equivalence margins narrower than the standard 80–125%.

Q7. Which statement best distinguishes a biosimilar from an interchangeable product in regulatory terms?

• A biosimilar is chemically identical; an interchangeable product is produced by the same manufacturer.
• A biosimilar demonstrates high similarity with no clinically meaningful differences; interchangeability additionally requires evidence that alternating between products does not increase risk and produces the same clinical result.
• Biosimilars require no clinical data; interchangeables require full clinical trials.
• There is no regulatory difference; the terms are synonymous worldwide.

Correct Answer: A biosimilar demonstrates high similarity with no clinically meaningful differences; interchangeability additionally requires evidence that alternating between products does not increase risk and produces the same clinical result.

Q8. Which statistical metric is recommended for comparing central tendency of log-normally distributed PK parameters in BE studies?

• Arithmetic mean difference.
• Median ratio with nonparametric CI.
• Geometric mean ratio (GMR) with log-transformed data.
• Mode comparison using t-test.

Correct Answer: Geometric mean ratio (GMR) with log-transformed data.

Q9. Which Biopharmaceutics Classification System (BCS) class is most clearly eligible for a biowaiver for immediate-release oral products?

• BCS Class IV — low solubility, low permeability.
• BCS Class III — high solubility, low permeability.
• BCS Class I — high solubility, high permeability.
• BCS Class II — low solubility, high permeability.

Correct Answer: BCS Class I — high solubility, high permeability.

Q10. Which level of in vitro–in vivo correlation (IVIVC) provides a point-to-point predictive relationship allowing prediction of the entire plasma time course from in vitro data?

• Level C — single-point correlation.
• Level B — statistical moment analysis correlation.
• Level A — highest level, point-to-point correlation.
• No correlation level; IVIVC is not applicable to oral products.

Correct Answer: Level A — highest level, point-to-point correlation.

Q11. Which assessments are essential when evaluating immunogenicity risk for a biosimilar?

• Only measuring total IgG levels in healthy volunteers.
• Comparative testing for anti-drug antibodies (binding and neutralizing) and assessment of clinical consequences such as loss of efficacy or adverse events.
• Measuring only complement activation in vitro.
• Relying solely on analytical similarity without clinical immunogenicity data.

Correct Answer: Comparative testing for anti-drug antibodies (binding and neutralizing) and assessment of clinical consequences such as loss of efficacy or adverse events.

Q12. What does the “totality of evidence” approach mean in the regulatory assessment of biosimilars?

• Decisions are based solely on large phase III clinical trials.
• Demonstration of similarity relies exclusively on manufacturing process documentation.
• A stepwise integration of analytical characterization, nonclinical data, PK/PD and limited clinical data to conclude biosimilarity.
• Approval based on price competitiveness combined with minimal testing.

Correct Answer: A stepwise integration of analytical characterization, nonclinical data, PK/PD and limited clinical data to conclude biosimilarity.

Q13. When is a PK/PD study an acceptable alternative to a clinical efficacy trial for demonstrating biosimilarity?

• When no PD markers exist and clinical endpoints are subjective.
• When there is a highly sensitive, specific, and reproducible PD marker that is directly related to clinical efficacy.
• For all monoclonal antibodies regardless of mechanism.
• Only when the reference product is withdrawn from market.

Correct Answer: When there is a highly sensitive, specific, and reproducible PD marker that is directly related to clinical efficacy.

Q14. What key advantage does a replicate crossover design provide in bioequivalence studies?

• It eliminates the need for washout periods completely.
• It allows estimation of within-subject variability for each formulation and enables reference-scaled approaches.
• It always reduces the required sample size below parallel designs irrespective of variability.
• It permits open-label administration of multiple doses without monitoring.

Correct Answer: It allows estimation of within-subject variability for each formulation and enables reference-scaled approaches.

Q15. Which primary PK parameter is most directly used to assess the extent of drug absorption?

• Cmax (maximum concentration).
• Tmax (time to maximum concentration).
• AUC (area under the concentration–time curve).
• Clearance (CL/F) only.

Correct Answer: AUC (area under the concentration–time curve).

Q16. What additional evidence is generally required for FDA interchangeability designation for a biosimilar?

• Only in vitro binding assays demonstrating higher potency than the reference.
• Switching studies showing that alternating or switching between the biosimilar and reference product does not increase risk or reduce efficacy.
• A single-arm open-label safety study in healthy volunteers.
• Proof that the biosimilar has a lower production cost.

Correct Answer: Switching studies showing that alternating or switching between the biosimilar and reference product does not increase risk or reduce efficacy.

Q17. Which population is typically preferred for bioequivalence studies of small-molecule oral drugs and why?

• Patients with the target disease to maximize clinical relevance.
• Healthy volunteers to reduce variability and minimize confounding disease effects.
• Only elderly volunteers because they represent worst-case pharmacokinetics.
• Newborns and pediatric subjects due to sensitive endpoints.

Correct Answer: Healthy volunteers to reduce variability and minimize confounding disease effects.

Q18. Which factors primarily determine sample size calculation for a bioequivalence study?

• Only the cost of the drug and number of investigators.
• Within-subject variability, expected geometric mean ratio, chosen bioequivalence limits, significance level (alpha), and desired power.
• The number of study sites and number of batches manufactured.
• Length of the washout period and the volume of blood collected.

Correct Answer: Within-subject variability, expected geometric mean ratio, chosen bioequivalence limits, significance level (alpha), and desired power.

Q19. Which elements are essential in validating a bioanalytical method used for PK measurement in BE studies?

• Only accuracy at the highest concentration is required.
• Validation for accuracy, precision, selectivity/specificity, stability, recovery and a suitable LLOQ.
• Visual inspection of chromatograms without quantitation limits.
• Validation only for assay speed and throughput.

Correct Answer: Validation for accuracy, precision, selectivity/specificity, stability, recovery and a suitable LLOQ.

Q20. How does an equivalence trial differ conceptually from a non-inferiority trial?

• Equivalence trials test if the test is strictly superior to reference; non-inferiority tests for equivalence.
• Equivalence trials aim to show the difference lies within a two-sided predefined margin (both directions), while non-inferiority tests only that the test is not unacceptably worse than reference (one-sided).
• There is no statistical difference; both use identical one-sided margins.
• Non-inferiority requires smaller sample sizes always compared to equivalence trials.

Correct Answer: Equivalence trials aim to show the difference lies within a two-sided predefined margin (both directions), while non-inferiority tests only that the test is not unacceptably worse than reference (one-sided).

Download